ArticleImmunity2018
An Interleukin-23-Interleukin-22 Axis Regulates Intestinal Microbial Homeostasis to Protect from Diet-Induced Atherosclerosis.
Article in Immunity, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
106 citing papers in PubMed, 1 synthesis or guideline pooled it, 182 citations in OpenAlex.
- MetaPhlAn 4 profiling of unknown species-level genome bins improves the characterization of diet-associated microbiome changes in mice.Cell reports · 2023Pooled it
- EAT-Lancet Diet-Associated Serum Metabolites Are Linked to Cardiovascular Disease and Mortality.The Journal of nutrition · 2026Article
- Diversity of oligosaccharides in lipooligosaccharides of Akkermansia muciniphila and its anti-atherosclerotic activity.Natural products and bioprospecting · 2026Article
- Pediatric and adult point of view on the gut-kidney axis in CKD.Pediatric nephrology (Berlin, Germany) · 2026Review
- T cells in cardiovascular disease: solved and unsolved mysteries.Science China. Life sciences · 2026Review
- Gut microbiota dysbiosis-induced chronic inflammation as a driver of atherosclerosis: cellular crosstalk and host-microbe interactions.Frontiers in cellular and infection microbiology · 2026Review
- Microbiota-derived metabolites in hematopoietic regulation and disease: mechanisms, context, and therapeutic perspectives.Frontiers in microbiology · 2026Review
- Inflammatory immune mechanisms underlying the comorbidity of psoriasis and atherosclerosis: clinical implications.Frontiers in immunology · 2026Review
- 25-Hydroxycholesterol restricts human norovirus replication in human intestinal enteroids.Journal of virology · 2025Article
- Article
- Impact of Biologics on Comorbidities in Patients with Psoriasis or Psoriatic Arthritis.Biomedicines · 2025Article
- Gut microbiota: a novel strategy affecting atherosclerosis.Microbiology spectrum · 2025Review
- Regulation of innate lymphoid cell by microbial metabolites.Journal of molecular medicine (Berlin, Germany) · 2025Review
- Exploring and evaluating microbiome resilience in the gut.FEMS microbiology ecology · 2025Review
- Weathering the Storm: How Age and Biologics Influence the COVID-19 Cytokine Surge.Pathogens (Basel, Switzerland) · 2025Review
- Cardiovascular disease risk in patients with psoriasis receiving biologics targeting TNF-α, IL-12/23, IL-17, and IL-23: A population-based retrospective cohort study.PLoS medicine · 2025Article
- The oral-gut microbiota axis: a link in cardiometabolic diseases.NPJ biofilms and microbiomes · 2025Review
- Progress in macrophage immune regulation of atherosclerosis.American journal of translational research · 2025Review
- TNF superfamily molecules in atherosclerosis: mechanistic insights and therapeutic translation.Frontiers in immunology · 2025Review
- Hemopexin and HO-1 induction during acute colitis in mice is dependent on interleukin-22.Frontiers in immunology · 2025Article
46 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
15 authors at 6 institutions in 1 country.
Funding
Abstract
Although commensal flora is involved in the regulation of immunity, the interplay between cytokine signaling and microbiota in atherosclerosis remains unknown. We found that interleukin (IL)-23 and its downstream target IL-22 restricted atherosclerosis by repressing pro-atherogenic microbiota. Inactivation of IL-23-IL-22 signaling led to deterioration of the intestinal barrier, dysbiosis, and expansion of pathogenic bacteria with distinct biosynthetic and metabolic properties, causing systemic increase in pro-atherogenic metabolites such as lipopolysaccharide (LPS) and trimethylamine N-oxide (TMAO). Augmented disease in the absence of the IL-23-IL-22 pathway was mediated in part by pro-atherogenic osteopontin, controlled by microbial metabolites. Microbiota transfer from IL-23-deficient mice accelerated atherosclerosis, whereas microbial depletion or IL-22 supplementation reduced inflammation and ameliorated disease. Our work uncovers the IL-23-IL-22 signaling as a regulator of atherosclerosis that restrains expansion of pro-atherogenic microbiota and argues for informed use of cytokine blockers to avoid cardiovascular side effects driven by microbiota and inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.